U.S. markets open in 5 hours 46 minutes
  • S&P Futures

    4,389.75
    -4.75 (-0.11%)
     
  • Dow Futures

    34,876.00
    -77.00 (-0.22%)
     
  • Nasdaq Futures

    14,928.50
    -19.25 (-0.13%)
     
  • Russell 2000 Futures

    2,189.80
    +3.10 (+0.14%)
     
  • Crude Oil

    71.94
    +0.29 (+0.40%)
     
  • Gold

    1,803.40
    +3.60 (+0.20%)
     
  • Silver

    24.81
    +0.16 (+0.63%)
     
  • EUR/USD

    1.1813
    -0.0013 (-0.11%)
     
  • 10-Yr Bond

    1.2340
    0.0000 (0.00%)
     
  • Vix

    19.36
    +1.78 (+10.13%)
     
  • GBP/USD

    1.3879
    +0.0000 (+0.00%)
     
  • USD/JPY

    109.8600
    +0.0930 (+0.08%)
     
  • BTC-USD

    39,878.11
    +2,841.71 (+7.67%)
     
  • CMC Crypto 200

    934.43
    +58.20 (+6.64%)
     
  • FTSE 100

    7,000.61
    +4.53 (+0.06%)
     
  • Nikkei 225

    27,581.66
    -388.56 (-1.39%)
     

Onychomycosis Treatment Market: Growing Prevalence Globally and Expected Entry of New Therapies Shall Drive the Market at a 4.22% CAGR During the Study Period [2018-2030], Analyses DelveInsight

·10 min read

Moberg Pharma is developing MOB-015, which is believed to be the most successful therapy amongst all the other expected drug candidates and shall account for the highest Onychomycosis market revenue in the coming years

LAS VEGAS, July 22, 2021 /PRNewswire/ -- DelveInsight's "Onychomycosis Market" report provides a thorough comprehension of the Onychomycosis historical and forecasted epidemiology and the Onychomycosis market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Onychomycosis market report also proffers an analysis of the current Onychomycosis treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

DelveInsight Logo
DelveInsight Logo

Some of the necessary takeaways from the Onychomycosis Market Research Report

  • Several key pharmaceutical companies include Pfizer, Bausch Health, Sato Pharmaceutical, Eisai, Moberg Pharma, Blueberry Therapeutics, Mycovia Pharmaceuticals, Meiji Seika Pharma, NovaBiotics, Hallux, and others, are developing novel products to improve the Onychomycosis treatment outlook.

  • In July 2014, the FDA approved Kerydin (Tavaborole) to treat Onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes. Tavaborole prohibits protein synthesis by inhibition of an aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS).

  • The FDA approved Jublia in July 2014 for the Onychomycosis treatment due to Trichophyton rubrum or Trichophyton mentagrophytes. Jublia has been marketed under the brand name Clenafin (Kaken Pharmaceuticals) in Japan since 2014.

  • A luliconazole 5% solution (Luconac R) was developed by Pola Pharma and Sato Pharmaceutical and launched in Japan in 2016 after securing approval from PMDA.

  • The Onychomycosis market to be driven by the factors such as advancements in clinical trials, promising results of emerging therapies, and wide acceptance of topical therapies. However, the long duration of Onychomycosis treatment, discontinuation of drug developments, and underdiagnosis of the disease may impede the Onychomycosis market growth.

For further information on Market Impact by Therapies, visit: Onychomycosis Drugs Market Analysis

Onychomycosis is a fungal infection of the nail, causing discoloration and thickening of the affected nail plate. The disease is the most common nail infection worldwide.

DelveInsight estimates that the Onychomycosis prevalent population in the United States was found to be 36,500,979 cases in 2020, whereas the total prevalent cases in the 7MM was 82,830,728.

The Onychomycosis Market Analysis Report provides historical as well as forecasted epidemiological analysis segmented into:

  • Diagnosed Onychomycosis prevalent cases

  • Prevalent cases of Onychomycosis by subtype

  • Onychomycosis Prevalence by Severity

Get a complete epidemiological segmentation breakdown @ Onychomycosis Epidemiological Analysis

Onychomycosis Treatment Market

Several Onychomycosis treatment options are available, including oral antifungals, topical antifungals, and devices. Oral antifungals have higher treatment cure rates and shorter treatment periods than topical treatments but have severe side effects such as hepatotoxicity and drug interactions. Topical treatments have less serious side effects but result in lower cure rates generally and much longer treatment regimens. Besides, new topical formulations are being investigated as faster-acting alternatives to the currently available topical treatments.

Currently, oral Terbinafine hydrochloride (Lamisil) is the most common treatment for Onychomycosis. It was approved by the US FDA and has been the mainstay with all its generic versions marketed since the patent expiry in 2007. Oral terbinafine is associated with safety issues, including drug interactions and liver damage.

A luliconazole 5% solution (Luconac R), which Pola Pharma and Sato Pharmaceutical developed, is an antifungal that belongs to the azole class. The other recently approved drug in Japan is NAILIN (fosravuconazole), currently marketed and manufactured by Sato Pharmaceutical Co., Ltd. This is the first new treatment for Onychomycosis that has improved bioavailability as compared to ravuconazole. In the process, Sato Pharma has attained the ability to provide externally and internally administered medicines as options for the Onychomycosis treatment.

Numerous attempts have been made to develop remedies for toenail fungus. Still, to date, the few products the FDA approved are currently dominating the Onychomycosis market are considered as a poor treatment option primarily for two significant reasons. Topical formulations deliver low cure rates and suboptimal efficacy. They cannot penetrate the nail plate to reach the infected nail bed in adequate concentrations to kill the fungus and may require debridement of the nail plate before application.

The complete cure rates are meager in the treatment modalities, and hepatotoxicity is a common side effect associated with prolonged usage. Onychomycosis patients must undertake periodic lab tests to ensure that their liver is functioning correctly while on the product. The numerous pharma players such as Moberg Pharma, Meiji Seika Pharma Co., Ltd., NovaBiotics, Hallux, and others have targeted this high unmet need to tap the Onychomycosis market and move forward towards overcoming the unmet needs.

The drug candidate MOB-015 by Moberg Pharma is a new topical treatment for Onychomycosis with fungicidal, keratolytic, and emollient properties. It is an internally developed topical formulation of terbinafine based on its experience from previously developed and commercialized OTC products for Onychomycosis.

Another candidate, ME1111, being developed by Meiji Seika Pharma Co., Ltd., is a topical formulation based on a novel class of compounds with a unique mode of action.

NP213 (Novexatin) by NovaBiotics is a unique compound for the treatment of Onychomycosis that addresses both the clinical and cosmetic issues associated with Onychomycosis. It rapidly kills fungi causative of nail infections by perturbing and lysing their outer membrane.

HTS-519 micro-insert being developed by Hallux, which can deliver high concentrations of terbinafine directly to the site of infection.

As many potential therapies are being investigated for Onychomycosis management, the treatment space will experience significant reconstitution during the forecast period of 2020-2030. Lack of awareness among the patient population leads to lower diagnosis and higher treatment duration, leading to low adherence. Improved safety and efficacy remain a major challenge, though emerging players have reported improved results. Currently approved therapies have very low mycological as well as clinical cure rates, thereby presenting the emerging players with a highly untapped market.

Scope of the Onychomycosis Market Insight Report

  • Onychomycosis Market Segmentation report provides detailed information about each region: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, and how numerous factors of that particular region affect the growth of the Onychomycosis market.

  • Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).

  • Onychomycosis Markets Segmentation proffers in the report as: By Geographies and By Onychomycosis Therapies (Historical and Forecasted, Current and Upcoming)

  • Dominant Market Companies investigate its candidates for Onychomycosis: Pfizer, Bausch Health, Sato Pharmaceutical, Eisai, Moberg Pharma, Blueberry Therapeutics, Mycovia Pharmaceuticals, Meiji Seika Pharma, NovaBiotics, Hallux, and several others.

  • Onychomycosis Pipeline Analysis provides a comparative and conjoint analysis of emerging therapies.

  • The report includes KOLs and SME's opinions working in the Onychomycosis domain through primary research to fill the data gaps and validate the secondary research to keep up with current Onychomycosis market trends, along with Case Studies and Analyst's Views.

  • Competitive and Market Intelligence analysis of the Onychomycosis Market is evaluated by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, and others.

Request for a Webex demo of the report @ Onychomycosis Therapeutics Market

Table of Contents

1

Onychomycosis Key Insights

2

Executive Summary of Onychomycosis

3

SWOT Analysis for Onychomycosis

4

Onychomycosis Market Overview at a Glance

5

Onychomycosis Disease Background and Overview

6

Onychomycosis Epidemiology and Patient Population

7

Country Wise-Epidemiology of Onychomycosis

7.1

The United States

7.2

EU5 Countries

7.2.1

Germany

7.2.2

France

7.2.3

Italy

7.2.4

Spain

7.2.5

The United Kingdom

7.3

Japan

8

Onychomycosis Treatment and Management

9

Onychomycosis Patient Journey

10

Onychomycosis Unmet Needs

11

Onychomycosis Marketed Products

11.1

Kerydin (tavaborole): Pfizer

11.2

Jublia/Clenafin (efinaconazole): Bausch Health

11.3

Luliconazole: Sato Pharmaceutical/Bausch Health

11.4

Nialin: Sato Pharmaceutical/ Eisai

12

Onychomycosis Emerging Therapies

12.1

MOB015: Moberg Pharma

12.2

BB2603: Blueberry Therapeutics

12.3

VT-1161: Mycovia Pharmaceuticals

13

Other Onychomycosis Promising Candidates

13.1

ME1111: Meiji Seika Pharma

13.2

NP213 (Novexatin): NovaBiotics

13.3

HTS-519: Hallux

14

Onychomycosis Discontinued Products

14.1

P3058: Almirall

15

Onychomycosis 7MM Market Analysis

15.1

The United States Onychomycosis Market Size

15.2

EU-5 Onychomycosis Market Size

15.2.1

Germany Market Size

15.2.2

France Market Size

15.2.3

Italy Market Size

15.2.4

Spain Market Size

15.2.5

The United Kingdom Market Size

15.2.3

Japan Onychomycosis Market Size

16

Onychomycosis Case Reports

17

Onychomycosis Market Drivers

18

Onychomycosis Market Barriers

19

Appendix

20

DelveInsight Capabilities

21

Disclaimer

22

About DelveInsight

Browse full report with detailed TOC with charts, figures, tables @ Onychomycosis Diagnostics Market Report

View Related Reports

DelveInsight's Onychomycosis - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Onychomycosis.

Onychomycosis Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Onychomycosis market. Notable companies such as Moberg Pharma, Polichem S.A., Mycovia Pharmaceuticals, Blueberry Therapeutics, NovaBiotics, Viamet, Meiji Seika Pharma, Hallux, Inc., Hexima, Kaken Pharmaceutical, Turn therapeutics, DX Discovery, and others are working on the therapies to improve Onychomycosis treatment scenario.

DelveInsight's Hyperopia Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of the historical, and forecasted epidemiology of Hyperopia. Key companies involved are Nevakar, and others for the development of Hyperopia therapies.

DelveInsight's "Chronic Pain Associated with Painful Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding, historical and forecasted epidemiology as well as the market trends in the 7MM.

DelveInsight's Eosinophilic Esophagitis Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology as well as the market trends in the 7MM. Key companies such as Dr Falk Pharma GmbH, Takeda, Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, and others are involved in developing Eosinophilic Esophagitis therapies.

DelveInsight's Acute Ocular Pain Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology as well as the market trends in the 7MM. Key companies such as Ocular Therapeutix, Kala Pharmaceuticals, Bausch & Lomb, Formosa Pharmaceuticals, and others are involved in developing Acute Ocular Pain therapies.

DelveInsight's Presbyopia Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology as well as the market trends in the 7MM. Key companies such as Allergan (acquired by AbbVie), Eyenovia, Orasis Pharmaceuticals, Ocuphire Pharma, Novartis, Visus Therapeutics, and others are involved in developing Presbyopia therapies.

DelveInsight's Night Vision Disturbances Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology. Key companies involved are Ocuphire Pharma, and others for the development of Night Vision Disturbances therapies.

Browse Blog Posts

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.

Contact Us:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/onychomycosis-treatment-market-growing-prevalence-globally-and-expected-entry-of-new-therapies-shall-drive-the-market-at-a-4-22-cagr-during-the-study-period-20182030-analyses-delveinsight-301339682.html

SOURCE DelveInsight Business Research, LLP